Analyst Benjamin Jackson CFA of Jefferies maintained a Buy rating on Galderma Group AG (GALD – Research Report), retaining the price target of CHF112.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s promising growth prospects. The company’s management has demonstrated confidence in their mid-term growth ambitions, which is supported by the dynamics within the Injectable Aesthetics market. Furthermore, the ongoing launch of Nemluvio, aimed at treating atopic dermatitis and prurigo nodularis, is expected to contribute positively to the company’s performance.
Additionally, the company’s strategic positioning and ability to navigate recent political developments in the US are seen as advantageous. These elements, combined with the insights shared by Galderma’s CEO, Flemming Ørnskov, during the upcoming fireside chat, reinforce the optimism surrounding the company’s future trajectory. As a result, Benjamin Jackson CFA believes that Galderma Group AG is well-positioned for growth, justifying the Buy rating.